LynxCare Blog

Discover how we help hospitals and life sciences collaborate under a federated model, and generate qualitative RWE at scale. Let’s grow the European Health Data Space, together.

Filter

Reset all
Show Filter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 03, 2023 - 1 min. read
Clinical Insights in Oncology
This is some text inside of a div block.
This is some text inside of a div block.
LynxCare's comprehensive data assets* offer fresh insights into Immuno-Oncology, Breast Cancer, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM), including comorbidity factors, treatment patterns, and staging.
re- re2-
Read more
Jun 27, 2023 - 4 min. read
The European Health Data Space: an opportunity to improve health for all.
This is some text inside of a div block.
This is some text inside of a div block.
In May 2022, the European Commission announced the launch of the European Health Data Space (EHDS), one of the central building blocks of a strong European Health Union. The EHDS will help the EU to achieve a quantum leap forward in the way healthcare is provided to people across Europe.
re- re2-
Read more
Latest news - Apr 17, 2023 - 5 min. read
Announcing LynxCare’s €20M series A Funding: the Next Step Towards More Transparency for Patients
Sep 01, 2023 - 2 min. read
Unlock Insights in Immuno-Oncology
This is some text inside of a div block.
This is some text inside of a div block.
With over 2000 estimated patients and 579 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of immuno-oncology (IO), empowering clinicians to make informed decisions.
re- re2-
Read more
Aug 01, 2023 - 3 min. read
The pivotal role RWE can play in transforming lung cancer care
This is some text inside of a div block.
This is some text inside of a div block.
We discuss the potential of the abundant RWD for lung cancer presenting an invaluable resource when translated into RWE. While clinical trials are essential, they may not fully represent the real-world patient population. RWE complements clinical trial evidence by providing insights on treatment outcomes in broader, unselected patient groups, helping inform reimbursement decisions and ensuring access to innovative therapies.
re- re2-
Read more
Jul 03, 2023 - 2 min. read
Real-World Evidence (RWE) to revolutionize regulatory decision-making in medicine in Europe
This is some text inside of a div block.
This is some text inside of a div block.
In its latest report released in June 2023, the EMA highlights key opportunities and challenges to move towards an optimized usage of RWE across the spectrum of regulatory use cases. To push this transformative vision forward, the report presents a list of lessons learned and recommendations. Continue reading below.
re- re2-
Read more
Jun 27, 2023 - 8 min. read
Real-World Evidence to support your research throughout the drug development lifecycle
This is some text inside of a div block.
This is some text inside of a div block.
A study published in Clinical Pharmacology &Therapeutics [1] looking at positive marketing authorization applications of new medicines by the European Medicines Agency (EMA) in 2018-2019, found that almost all evaluated medicines included RWE signatures in the discovery (98.2%) and lifecycle management (100%) phases. About half of the medicines had RWE signatures for the full development phase (48.6%) and for supporting regulatory decisions at the registration phase (46.8%), while over a third included RWE signatures for the early development (35.1%). Therapeutic areas such as oncology, hematology, and anti-infectives showed the highest use of RWE signatures in their full development phase.
re- re2-
Read more
Jun 10, 2023 - 5 min. read
Accelerating Clinical Research: Using Big Data to Fast-Track Patient Selection
This is some text inside of a div block.
This is some text inside of a div block.
Selecting patients for clinical studies can be a slow and tedious process. But it does not have to be. Emerging technologies are paving the way for faster and more efficient patient selection, and our Clinical REsearch Patient Selection (CREPS) project in collaboration with a renowned Belgian hospital is leading the change. In this blog post, we will dive into the world of real-world evidence (RWE) and explore how the use of big data and Natural Language Processing (NLP) can revolutionize the way we screen and select patients for clinical studies while always remaining 100% GDPR compliant. Let us explore how LynxCare’s technology can speed up and simplify your trials’ patient selection process.
re- re2-
Read more
May 15, 2023 - 3 min. read
The potential of Natural Language Processing in cardiology is becoming increasingly apparent
This is some text inside of a div block.
This is some text inside of a div block.
A metanalysis published in the Heart journal identified 37 studies developing and applying NLP in various areas of cardiology. This systematic review found that the majority of NLP work in cardiology has been concentrated in a small number of clinical domains and NLP methods, with the most common applications being used for disease identification and classification purposes. Patient sample sizes ranged from 60 to 621,000. Data sources ranged from single centers to national healthcare system databases and registries, most of them taking place in the US.
re- re2-
Read more

Curious what LynxCare can do for you?

For Life Science organizations

RWE you can trust. At scale.

Discover how
For Healthcare organizations

Put your data to work.

Discover how

”We're an active contributor to establishing the pan-European Health Data Evidence Network (EHDEN) and are eager to contribute to building the European Health Data Space to make a more inclusive European healthcare system for all patients.”

Georges De Feu
Co-founder & CEO, LynxCare